Leap Therapeutic SEC Filings

Cypherpunk Technologies Inc. filed an initial beneficial ownership statement for a director. The Form 3 indicates the reporting person serves as a director and, as of the event date 11/11/2025, reports no securities beneficially owned. The submission includes an Exhibit 24 Power of Attorney authorizing the filing. This is an administrative disclosure under Section 16 and does not reflect a transaction or change in the company’s capital.

Cypherpunk Technologies Inc. (NASDAQ: LPTX) established an at-the-market equity program, allowing sales of common stock of up to $200,000,000 through Cantor Fitzgerald & Co., which may act as sales agent or principal.

Sales may be made from time to time as “at the market offerings” under Rule 415. Cantor will receive a commission of up to 3.0% of gross proceeds. The company can suspend offers at any time, and either party may terminate the agreement with ten business days’ notice. Shares will be issued off the company’s effective Form S-3 shelf, with sales made pursuant to a prospectus supplement. The company also noted its corporate name change to Cypherpunk Technologies Inc., effective November 12, 2025.

Cypherpunk Technologies Inc. (formerly Leap Therapeutics) launched an at-the-market equity program to sell up to $200,000,000 of common stock from time to time through Cantor Fitzgerald under a Controlled Equity Offering Sales Agreement. Cantor may act as sales agent or principal and will receive a commission of up to 3.0% of the gross sales price. Shares will be sold pursuant to Rule 415 after mutually agreed instructions; there is no escrow arrangement.

The company expects to use net proceeds for working capital and general corporate purposes, including acquiring Zcash (ZEC) as its primary treasury reserve asset. As of November 11, 2025, Cypherpunk had acquired 203,775.27 ZEC at an aggregate purchase price of approximately $50.0 million. The company’s Nasdaq symbol is expected to change from LPTX to CYPH. 56,651,840 shares were outstanding as of November 11, 2025; this is a baseline figure, not the amount being offered. The last reported sale price was $0.4375 per share on November 11, 2025.

Cypherpunk Technologies Inc. (formerly Leap Therapeutics) filed its Q3 2025 10‑Q, reporting a smaller quarterly loss and a major strategic shift. The company posted a Q3 net loss of $3.3 million on operating expenses of $3.2 million, reflecting a significant year-over-year reduction in R&D and G&A. Cash and cash equivalents were $9.7 million at September 30, 2025, down from $47.2 million at year‑end.

After quarter‑end, Cypherpunk raised gross proceeds of $58.888 million in an October 2025 private placement of common stock, pre‑funded warrants, and common warrants, with approximate net proceeds of $57 million. The company disclosed that $7 million of the net proceeds will support operations, and it initiated a digital asset treasury strategy focused on Zcash (ZEC). Subsequent to quarter‑end, it purchased 203,775 ZEC for $50.0 million at a weighted average cost of $245.37 per token.

The company changed its name to Cypherpunk Technologies Inc. and its Nasdaq ticker to CYPH, while placing biotechnology activities into a wholly owned subsidiary (Leap Therapeutics, Inc.). A June 2025 restructuring wound down R&D programs and reduced headcount by about 75%, resulting in $4.5 million in year‑to‑date restructuring charges. Shares outstanding were 56,651,840 as of November 10, 2025.

Cypherpunk Technologies Inc. (formerly Leap Therapeutics) announced a rebrand, leadership changes, large equity awards, and a new digital-asset treasury approach. The company used $50 million of private placement proceeds to buy 203,775 ZEC at a weighted average cost of $245.37 per token. Its Nasdaq ticker will change from LPTX to CYPH, effective at the market open on November 13, 2025.

The board appointed Khing Oei (non-executive Chairman) and William McEvoy as directors, with Mr. McEvoy also named Chief Investment Officer and eligible for 5,616,906 RSUs, subject to stockholder and plan-related approvals. A consulting agreement with CoinXit Ltd. includes an immediate grant of 2,411,700 RSUs and a contingent grant of 3,036,457 RSUs upon specified approvals. The compensation committee also approved an aggregate of 3,241,687 RSUs for directors and employees. The company adopted amended bylaws, formed a new subsidiary retaining the Leap Therapeutics name for R&D operations, and furnished Q3 2025 results via press release.

Leap Therapeutics called a virtual special meeting for December 15, 2025 to vote on five proposals tied to its recent financing and listing plans. The Board seeks to increase authorized shares to 500,000,000 (of which 490,000,000 would be common) and to authorize a reverse stock split within a 1:5 to 1:20 range to help regain Nasdaq minimum bid compliance.

Stockholders will also consider a new 2025 Equity Incentive Plan authorizing 22,500,000 shares (plus carryover from prior plans), and approval to issue shares above 19.99% of outstanding common upon warrant exercise from the October 2025 private placement—up to 152,754,109 shares under Nasdaq rules. An adjournment proposal is included.

In the October 2025 financing, Leap raised $58,888,888 in gross proceeds, issuing 15,212,311 shares and pre-funded warrants for 80,768,504 shares. Shares outstanding were 56,651,840 as of October 24, 2025. The Board unanimously recommends voting FOR all proposals.

Leap Therapeutics (LPTX) called a special stockholder meeting to vote on five proposals tied to its recent financing and listing compliance plans. The company completed a private placement for aggregate gross proceeds of $58,888,888, issuing 15,212,311 common shares, Pre-Funded Warrants for up to 80,768,504 shares, and Common Warrants for up to 71,985,605 shares at an exercise price of $0.5335 per share.

Stockholders will vote on: increasing authorized shares to 500,000,000 (490,000,000 common); authorizing a reverse stock split within a 1:5 to 1:20 range to help regain Nasdaq bid-price compliance; adopting the 2025 Equity Incentive Plan; and permitting issuance above 19.99% upon warrant exercise under Nasdaq rules, covering up to 152,754,109 shares. As of October 24, 2025, shares outstanding were 56,651,840. The company states proceeds support a digital asset treasury strategy and ongoing programs including FL-501 and sirexatamab.

Leap Therapeutics, Inc. filed an 8-K reporting a material event that attaches a resale registration statement and related agreements and exhibits. The filing specifies that the Resale Registration Statement must be kept continuously effective from the SEC effectiveness date until either the purchasers have resold all registrable securities or those securities become freely tradable under Rule 144 without volume or manner-of-sale limits and without reliance on the current public information requirement. The filing includes forms for a Common Warrant, Pre-Funded Warrant, a Securities Purchase Agreement, a Registration Rights Agreement, a Lead Investor Agreement, and a Press Release dated October 9, 2025. The document notes procedural timing tied to SEC operations (effectiveness timing can extend if the SEC is closed).